Holen Sie sich die Stockscreener-App
38.15
1.09%
-0.42
Handel nachbörslich:
37.79
-0.36
-0.94%
Schlusskurs vom Vortag:
$38.57
Offen:
$38.67
24-Stunden-Volumen:
2.93M
Relative Volume:
1.05
Marktkapitalisierung:
$10.27B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
21.55
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
-4.84%
1M Leistung:
+1.19%
6M Leistung:
+10.71%
1J Leistung:
+48.39%
1-Tages-Spanne:
$37.71
$38.71
1-Wochen-Bereich:
$37.71
$40.43
52-Wochen-Spanne:
$25.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.15 | 10.38B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Historical volatility pattern of Exelixis Inc. visualized2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Is Upward Earnings Estimate Momentum Altering The Investment Case For Exelixis (EXEL)? - Yahoo
Exelixis' (NASDAQ:EXEL) Earnings Growth Rate Lags the 35% CAGR Delivered to Shareholders - 富途牛牛
Is Exelixis Inc. forming a bottoming baseJuly 2025 Drop Watch & Weekly Setup with High ROI Potential - newser.com
Order flow analysis tools used on Exelixis Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
Real time breakdown of Exelixis Inc. stock performanceQuarterly Trade Review & Free Daily Entry Point Trade Alerts - newser.com
Is Exelixis Inc. (EX9) stock considered safe havenMarket Activity Report & Low Risk Entry Point Guides - newser.com
Can Exelixis Inc. stock sustain market leadership2025 Key Highlights & Weekly High Return Opportunities - newser.com
What analyst consensus says on Exelixis Inc. stock2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com
Advanced analytics toolkit walkthrough for Exelixis Inc.Buy Signal & Free Community Supported Trade Ideas - newser.com
Is Exelixis Inc. (EX9) stock supported by strong fundamentalsJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Is Exelixis Inc. (EX9) stock worth buying before Fed actionJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - sharewise.com
What does recent volatility data suggest for Exelixis Inc.Earnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Will earnings trigger a reversal in Exelixis Inc.GDP Growth & Safe Entry Trade Reports - newser.com
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
Exelixis Inc. stock volume spike explainedJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - newser.com
Automated trading signals detected on Exelixis Inc.Market Growth Review & AI Driven Price Forecasts - newser.com
Pattern recognition hints at Exelixis Inc. upside2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
How Exelixis Inc. stock performs in stagflationPortfolio Return Report & Weekly High Momentum Picks - newser.com
Is this a good reentry point in Exelixis Inc.Market Movement Recap & Expert Approved Momentum Ideas - newser.com
Exelixis shuttering Pennsylvania site, laying off 130 employees - MSN
What Risks Could Derail Master Trust Limiteds Growth Story in YEARMarket Entry Points & Superior Growth Trading - earlytimes.in
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - The Motley Fool
Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook - MSN
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Exelixis, Inc. (EXEL) Stock Analysis: A 13.38% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):